For the Inventor, By the Inventor

Enter inventor name

Versailles, France

Frederic Triebel

USPTO Granted Patents = 25 (Patent Applications = 15)

CIPO Patents = 4 (Patent Applications = 5)

EPO Patents = 1 (Patent Applications = 2)

Average Co-Inventor Count = 2.0

ph-index = 12

Forward Citations = 442(Granted Patents)

Location History:

Neuilly, FR (1998 - 1999)
Seine, FR (1998 - 2007)
Neuilly-sur-Seine, FR (2014)
Versailles, FR (1997 - 2023)

Company Filing History:

Institut Gustave Roussy

Institut National De La Sante Et De La Recherche Medicale

Applied Research Systems Ars Holding N.v.

5. 4 out of 854

6. 3 out of 377

Aventis Pharma S.a.

Immutep Parc Club Orsay

9. 1 out of 236

Hoechst Marion Roussel

11. 1 out of 832,891

Other

patents

where one patent can have more than one assignee

Years Active: 1997-2025

Loading Chart...

Loading Chart...

Loading Chart...

25 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12214012 - Combined preparations for the treatment of cancer (2025-02-04),

2. 11684654 - Combined preparations for the treatment of cancer or infection (2023-06-27),

3. 11583582 - Use of recombinant LAG-3 or the derivatives thereof for eliciting monocyte immune response (2023-02-21),

4. 10940181 - Combined preparations for the treatment of cancer or infection (2021-03-09),

5. 10874713 - Combined preparations for the treatment of cancer or infection (2020-12-29),

6. 10736940 - Combined preparations for the treatment of cancer (2020-08-11),

7. 10232038 - Use of recombinant LAG-3 or the derivatives thereof for eliciting monocyte immune response (2019-03-19),

8. 9244059 - Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease (2016-01-26),

9. 8709426 - Nucleotide sequence coding for variable regions of β chains of human T lymphocyte receptors, corresponding peptide segments and the diagnostic and therapeutic uses (2014-04-29),

10. 8425897 - Compositions containing LAG-3 and cells that secrete GM-CSF and methods of use (2013-04-23),

11. 7294712 - Nucleotide sequences coding for variable regions of β chains of human T lymphocyte receptors, corresponding peptide segments and the diagnostic and therapeutic uses (2007-11-13),

12. 7109026 - Use of MHC class II ligands as adjuvant for vaccination and of LAG-3 in cancer treatment (2006-09-19),

13. 6596536 - Nucleotide sequences coding for variable regions of the alpha chains of human T lymphocyte receptors, corresponding peptide segments and the diagnostic and therapeutic uses (2003-07-22),

14. 6482925 - Mutants of the LAG-3 proteins and nucleotides encoding LAG-3 mutants (2002-11-19),

15. 6410509 - Use of MHC class II ligands as adjuvant for vaccination and of LAG-3 in cancer treatment (2002-06-25),

Title: Inventor Frederic Triebel

Introduction: Frederic Triebel is a renowned inventor based in Versailles, France, known for his groundbreaking contributions to various fields.

Latest Patents: Frederic Triebel holds several patents in the areas of renewable energy technologies, medical devices, and advanced materials.

Career Highlights: With a career spanning over two decades, Triebel has worked on numerous innovative projects that have significantly impacted industries worldwide. His work has been recognized for its creativity and practicality.

Collaborations: Throughout his career, Frederic Triebel has collaborated with leading research institutions, universities, and companies to bring his inventions to life. His ability to work in multidisciplinary teams has led to the successful development of cutting-edge technologies.

Conclusion: Frederic Triebel's passion for innovation and his dedication to pushing the boundaries of what is possible make him a standout figure in the world of inventors. His work continues to inspire future generations of innovators.

This text is generated by artificial intelligence and may not be accurate.

Please report any incorrect information to support@idiyas.com

Loading…